Find clinical trials

This proposed study 817P203, is a Phase 2 double-blind, randomised, placebo-controlled, multicentre, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures. The study is planned to involve approximately 258 participants aged 18 to 70 years who have focal onset seizures at multiple study sites worldwide in the United States, Europe, and Asia Pacific. The study will have two groups of participants will be randomly assigned in a 2:1 ratio to SPN-817 (3.0 to 4.0 mg twice daily [BID]) or placebo, respectively, to achieve approximately 180 participants globally completing the study. The duration of treatment with SPN-817 or placebo will be approximately 22 to 24 weeks. The Primary Objective is to evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures. The Secondary Objectives are to evaluate the safety and tolerability of SPN-817 as a treatment for adult participants with focal onset seizures, and to characterize the pharmacokinetics (PK) of huperzine A after multiple dose administrations of SPN-817 (population PK analysis).

The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy among adults with metastatic non-small cell lung cancer (NSCLC).

The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems.

The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks).

During the study, participants will visit their study clinic several times.

This study aims to determine whether the small airways, a site of physiological dysfunction in asthma, can be targeted with bronchodilator therapy, by using a small particle size aerosol that reaches the lung periphery. Current clinical management of patients with asthma includes an array of inhaled therapies. However, there is no consensus relating to the efficacy of different particle sizes for inhalation, despite particle size being the main determinant of where the drug deposits in the airway. Participants with asthma will be invited to participate in two study visits. Both study visits will involve physiological assessments (lung function tests) and ventilation scans completed at baseline and post-bronchodilator. At one visit the standard medication salbutamol will be administered via a conventional vibrating mesh nebuliser (Aerogen solo), at the other visit the salbutamol will be administered via the Aerogen PDAP which will create a fine particle aerosol. The aim is 2 recruit and test 30 participants and compare their response to small and large particle bronchodilator.